Dactinomycin
- Generic Name
- Dactinomycin
- Brand Names
- Cosmegen
- Drug Type
- Small Molecule
- Chemical Formula
- C62H86N12O16
- CAS Number
- 50-76-0
- Unique Ingredient Identifier
- 1CC1JFE158
- Background
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (Fro...
- Indication
For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
- Associated Conditions
- Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Osteosarcoma, Ovarian Cancer, Rhabdomyosarcomas, Wilms' tumor, Metastatic nonseminomatous Testicular cancer
- Associated Therapies
- -
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionOther: Patient ObservationProcedure: Computed TomographyProcedure: Bone ScanDrug: CyclophosphamideBiological: DactinomycinProcedure: ResectionProcedure: Ultrasound ImagingDrug: DexrazoxaneDrug: VincristineDrug: DoxorubicinProcedure: EchocardiographyDrug: IfosfamideProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyDrug: Topotecan
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 110
- Registration Number
- NCT06647953
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
- Conditions
- Interventions
- Procedure: NephrectomyProcedure: Computed TomographyProcedure: Bone ScanDrug: CarboplatinBiological: DactinomycinOther: Patient ObservationProcedure: Magnetic Resonance ImagingDrug: DoxorubicinDrug: CyclophosphamideProcedure: Ultrasound ImagingDrug: VincristineDrug: EtoposideProcedure: X-Ray ImagingDrug: IrinotecanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1656
- Registration Number
- NCT06401330
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 36
- Registration Number
- NCT06309732
- Locations
- 🇬🇧
Barts and the London NHS Trust, London, United Kingdom
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06028672
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06023641
- Locations
- 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸Sanford University, Palo Alto, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7
- Conditions
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT06020755
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 205
- Registration Number
- NCT05304585
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇦🇺Sydney Children's Hospital, Randwick, New South Wales, Australia
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Bone ScanProcedure: Computed TomographyDrug: CyclophosphamideBiological: DactinomycinProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Radiation TherapyDrug: Vincristine SulfateDrug: Vinorelbine TartrateProcedure: X-Ray Imaging
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 118
- Registration Number
- NCT04994132
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 1672
- Registration Number
- NCT04625907
- Locations
- 🇬🇷
University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇮🇱Hadassah University Medical Centre, Jerusalem, Israel
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- xiang yang
- Target Recruit Count
- 228
- Registration Number
- NCT04562558
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.